• Modeling and Shared Compute Reveals Pathways of Synthetic Drug

    Dec 12 | Bio-IT World | Researchers from the University of Illinois Urbana-Champaign used deep learning and large-scale computer simulations to identify structural differences in synthetic cannabinoid molecules that cause them to bind to human brain receptors differently from classical cannabinoids. More

  • Rethinking Precision Oncology in the Age of Functional Data

    Dec 11 | Bio-IT World | Historically, cancer treatment has relied on a one-size-fits-all approach known as the Standard of Care, where patients are treated based on population averages. But cancer is not a single disease; it’s thousands of distinct conditions, each driven by unique biology. More

  • Oxford Nanopore's Newly Named CEO Brings Diagnostics Expertise

    Dec 08 | Bio-IT World | Oxford Nanopore Technologies named a new CEO this morning, choosing an executive with extensive diagnostics experience. Francis Van Parys, currently CEO of Radiometer, will join Oxford Nanopore and the Board as an Executive Director on March 2, 2026. More

  • National University of Singapore Launches First Global Medical AI Foundation Model

    Dec 04 | Bio-IT World | Since artificial intelligence (AI) made its way into the medical field, foundation models—machine learning systems that are trained on broad data and adaptable to a wide range of downstream tasks—have become a focus. These foundation models are used to perform various medical tasks with minimal amounts of data. Of course, this means that these models require robust training, which poses a challenge for researchers. More

  • How Next-Gen Biotechnology Is Transforming Genetic Risk Prediction

    Dec 03 | Bio-IT World | As genetic testing becomes a routine part of modern medicine, researchers are grappling with an unintended consequence: a flood of never-before-seen genetic variants whose clinical significance is unknown. These variants of uncertain significance (VUS), now number in the tens of thousands, outpace the capacity of traditional scientific methods to determine whether they contribute to disease. More

  • Psychedelics and Patient Selection Tools Propelling Precision Psychiatry

    Dec 02 | Bio-IT World | How depression gets treated in the next decade is poised for significant change thanks to encouraging developments in the use of psychedelics and dissociative compounds like ketamine to alleviate symptoms of the mood disorder. Scientific interest in psychedelic-based therapies has skyrocketed in recent years, driven by promising clinical trial outcomes, a flood of financial investment, and the urgent need for new treatments to counter a growing mental health crisis More

  • Follow the Money: Enveloped Delivery Vehicle Technology, Oral Medication for Inflammatory, Neurological Diseases, More

    Nov 25 | Bio-IT World | Azalea Therapeutics will advance their Enveloped Delivery Vehicle (EDV) technology; Gate Biosciences will advance inflammatory and neurological disease treatments through the convenience of a pill; and more. More

  • Eli Lilly to Open Lab in Philadelphia, QIAGEN to Acquire Parse Biosciences, Novartis Expands to North Carolina

    Nov 24 | Bio-IT World | Eli Lilly plans to open a new lab in Philadelphia; QIAGEN enters into a definitive agreement to fully acquire Parse Biosciences; Novartis announced plans to expand a flagship hub in North Carolina; and more. More

  • Ginkgo Datapoints Launches Virtual Cell Pharmacology Initiative

    Nov 21 | Bio-IT World | Ginkgo Datapoints has launched V-Ref293, a novel engineered cell line designated specifically as the reference standard for virtual cell research. Along with the cell line, the group is launching the Virtual Cell Pharmacology Initiative (VCPI), the first project under The Virtual Cell bio-AI community platform from Ginkgo Datapoints. More

  • The Women’s Health Gap: 5 Cautionary Tales of Clinical Blunders

    Nov 19 | Bio-IT World | Progress on women’s health, which was only truly recognized at the federal level when the Food and Drug Administration (FDA) asked for the inclusion of women in clinical trials in 1993, encountered a large obstacle earlier this year when the White House cut off a major funding initiative established by previous administrations intended to right the harms from decades of largely failing to include women in medical research. The move marks a succession of blind spot moments in the history of human research that have had damaging consequences for women. More
View more articles
Bio IT World Lead Gen

 
Industry-spotlight

Riffyn’s pioneering cloud system, Riffyn Nexus, delivers 2X faster development cycles and 4X productivity gains to the world’s most advanced scientific R&D organizations. Its process-centric experiment design, data capture, and data analytics overcome the limitations of ELN and LIMS systems. Its adaptive data integration engine delivers results that are always ready for machine learning.
Read more here!

Industry-spotlight
Trends from the Trenches

Bio-IT World’s Trends from the Trenches podcast delivers your insider’s look at the science, technology, and executive trends driving the life sciences through conversations with industry leaders. BioTeam co-founder Stan Gloss brings years of industry experience in science, data, and technology to conversations exploring what is driving data and discovery, and what’s coming next.
Listen today!